First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Cardiac safety and efficacy data from the herceptin, cyclophosphamide, and epirubicin (HERCULES) trial

Journal of Clinical Oncology

Volumn 28, Issue 9, 2010, Pages 1473-1480

  Untch, Michael ^a   Muscholl, Michael ^a   Tjulandin, Sergei ^a   Jonat, Walter ^a   Meerpohl, Hans Gerd ^a   Lichinitser, Mikhail ^a   Manikhas, Alexey G ^a   Coumbos, Alexandra ^a   Kreienberg, Rolf ^a   Du Bois, Andreas ^a   Harbeck, Nadia ^a   Jackisch, Christian ^a   Müller, Volkmar ^a   Pauschinger, Matthias ^a   Thomssen, Christoph ^a   Lehle, Michaela ^a   Catalani, Olivier ^a   Lück, Hans Joachim ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HEART DEATH; HEART FUNCTION; HUMAN; INFLUENZA; LEUKOPENIA; LIMB PAIN; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHINOPHARYNGITIS; STOMATITIS; TREATMENT REFUSAL; UPPER ABDOMINAL PAIN; VOMITING; BIOSYNTHESIS; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; HEART DISEASE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; HEART DISEASES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 77951918330     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.9709     Document Type: Article

References (29)

1. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997 (Pubitemid 27330017)
2. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
3. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993 (Pubitemid 23101563)
4. Cook-Bruns N: Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61:58-66, 2001 (suppl 2)
5. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005 (Pubitemid 46207001)
6. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial. J Clin Oncol 25:3859-3865, 2007 (Pubitemid 47477261)
7. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
8. Kaufman B, Mackey J, Clemens M, et al: Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC). Ann Oncol 17:LBA2, 2006 (suppl 9; abstr)
9. Jensen BV: Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 33:S15-S21, 2006 (suppl 8)
10. Findlay BP, Walker-Dilks C: Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer: Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 2:140-146, 1998
11. Hortobagyi GN, Yap HY, Kau SW, et al: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12:57-62, 1989 (Pubitemid 19037254)
12. Gianni L: Dose-adjusting epirubicin in patients with altered liver function: When classical pharmacology makes good practical sense. Eur J Cancer 39:557-559, 2003
13. Riccardi A, Tinelli C, Brugnatelli S, et al: Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: A prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer. Int J Oncol 16:769-776, 2000
14. Robert J: Epirubicin: Clinical pharmacology and dose-effect relationship. Drugs 45:20-30, 1993 (suppl 2)
15. Untch M, Eidtmann H, du Bois A, et al: Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: Results of a phase I trial. Eur J Cancer 40:988-997, 2004 (Pubitemid 38496254)
16. Schiller NB, Shah PM, Crawford M, et al: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358-367, 1989
17. Konecny G, Pauletti G, Pegram M, et al: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142-153, 2003 (Pubitemid 36193263)
18. Suter TM, Cook-Bruns N, Barton C: Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13:173-183, 2004 (Pubitemid 38937119)
19. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005
20. Romond EH, Perez EA, Bryant J, et al: Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer: Combined analysis of NSABP-B31/NCCTG-N9831. Slide presentation at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005
21. Untch M, Rezai M, Loibl S, et al: Evaluating the efficacy and safety of trastuzumab given concomitantly to epirubicin/cyclophosphamide → docetaxel ± capecitabine as neoadjuvant treatment of HER2 overexpressing primary breast cancer: First analysis of the GBG/AGO intergroup-study "Gepar-Quattro." Breast Cancer Res Treat 106:5053, 2007 (suppl 1; abstr)
22. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: Primary efficacy analysis of the NOAH trial. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008 (abstr 31)
23. Rastogi P, Jeong J, Geyer CE, et al: Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)→paclitaxel (T) compared to AC→T with trastuzumab (H). J Clin Oncol 25:6s, 2007 (suppl 18S; abstr LBA513)
24. Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233, 2007 (Pubitemid 46121873)
25. Theodoulou M, Hudis C: Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 100:2052-2063, 2004
26. Verma S, Dent S, Chow BJ, et al: Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 34:391-406, 2008
27. Chia S, Clemons M, Martin L-A, et al: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial. J Clin Oncol 24:2773-2778, 2006 (Pubitemid 46630575)
28. Wolff AC, Wang M, Sparano JA, et al: Cardiac safety and clinical activity of pegylated liposomal doxorubicin (D) and docetaxel (T) with and without trastuzumab (H) as 1st line chemotherapy in HER2-positive and HER2-negative metastatic breast cancer (MBC): Eastern Cooperative Oncology Group (ECOG) trial E3198. Breast Cancer Res Treat 88:3040, 2004 (suppl 1; abstr)
29. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)